• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

May 8, 2013: Vaccines and Related Biological Products Advisory Committee Meeting Draft Agenda

Food and Drug Administration
Center for Biologics Evaluation and Research
Vaccines and Related Biological Products Advisory Committee
133rd Meeting via Teleconference
Rockwall II, Conference Room 1033
5515 Security Lane, Rockville, MD
May 8, 2013

DRAFT AGENDA

  Open Session
1:00 p.m. Call to Order and Opening Remarks
Robert Daum, M.D., Chair

Conflict of Interest Statement
Donald Jehn, M.S., FDA
Topic I
Presentation of Laboratory of DNA Viruses,
Division of Viral Products,
Office of Vaccines Research and Review,
Center for Biologics Evaluation and Research
1:15 Overview of Research/Site Visit Process,
Carolyn Wilson, Ph.D., FDA
Center Biologics Evaluation and Research (CBER)
1:35 Overview Division of Viral Products, OVRR
Jerry Weir, Ph.D., FDA
1:50 Overview Laboratory of DNA Viruses
Keith Peden, Ph.D., FDA
2:20 Open Public Hearing
3:20 Closed Session
4:00 Adjourn Meeting